Worth reading
82Important
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
12.7
Year-on-year increase in net sales (%)Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials on financial resultsFiscal year ending June 202611 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥6,155 million+12.7%
Operating profit¥1,127 million+23.9%
Ordinary income¥1,131 million+24.6%
Net income¥939 million+58.4%
Operating profit margin18.3%; no year-on-year change information was specified in the materials
Results for the three months of the current quarter
Q4 of the fiscal year ended June 2026
Net Sales
¥1,837 million
Operating profit
¥453 million
Full-year earnings forecast
Fiscal year ending June 2027
Net Sales
¥7,535 million
Operating profit
¥1,569 million
Ordinary income
¥1,569 million
Profit attributable to owners of the parent
¥1,005 million
EBITDA
¥1,954 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
All revenue and profit targets at each level were achievedBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Operating profit
Revenue increase¥692 million
Personnel Expenses¥-242 million
Procurement¥-98 million
Goodwill amortization¥-19 million
Other¥-115 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
New M&ANot included in the forecast due to uncertainty over the timing of opening
New Hospital OpeningsNot included in the forecast due to uncertainty over the timing of opening
ScopeAssumes only revenue growth from existing businesses and confirmed M&A transactions
New initiatives
- Strategic M&A to build a One Health platform
- Launch of sales of Photo Barrier405
- Planned launch of the Craft model disinfecting and deodorizing machine
- Proof-of-concept research on technology to inactivate avian influenza viruses
- Succession of the chitin nanofiber business and opening of the Tottori Factory
- Joint research with DynaCom on the use of veterinary medical data
- Making メディトリックス a wholly owned subsidiary
- Appointment of Dr. Ichikawa Yasuaki (市川康明) as co-director of the Institute of Advanced Veterinary Medicine
Key KPIsA metric the company considers important as a management benchmark.
- EBITDA¥1,511 millionYear on year against the same period last year+20.0%
- EBITDA margin24.6 %Year on year against the same period last year+1.5 percentage points
- Number of animal hospitals39 HospitalsYear on year against the same period last year+1 hospital
- Number of medical cases12.5 ten thousand itemsYear on year against the same period last yearIncreased
- Average medical service price¥448 thousandYear on year against the same period last yearIncreased
Unit price and quantity metricsThese figures show sales broken down by price and volume.
Number of medical cases
12.5 ten thousand items
Average medical service price
¥448 thousand
Segment results
Animal hospital network business
Net Sales
¥5,763 million
Ordinary income
¥1,046 million
Operating margin18.1%
Medical and hygiene equipment business
Net Sales
¥268 million
Ordinary income
¥64 million
Operating margin23.8%
Biomaterials Business
Operating margin0.0%
Medical data solutions business
Net Sales
¥125 million
Ordinary income
¥22 million
Operating margin17.8%
Contract research and development business
Operating margin0.0%
Number of stores and locations
End of period39 Hospitals/sites
Number of store openings and closures during the period21 sites acquired through business succession, a net increase of 5 self-established sites, and 4 closures
Capital expenditures
¥189 million acquisitions of property, plant and equipment
Annual Dividend
An initial dividend is scheduled to be paid from the fiscal year ending June 2027; the dividend per share is not disclosedPayout ratio
Based on a 20% payout ratio| Item | Details |
|---|---|
| Document type | Presentation materials on financial results |
| Fiscal Period Covered | Fiscal year ending June 2026 |
| Net Sales | ¥6,155 million (YoY +12.7%) |
| Operating profit | ¥1,127 million (YoY +23.9%) |
| Ordinary income | ¥1,131 million (YoY +24.6%) |
| Net income | ¥939 million (YoY +58.4%) |
| Operating profit margin | 18.3%; no year-on-year change information was specified in the materials |
| Results for the three months of the current quarter | Q4 of the fiscal year ended June 2026 Net Sales ¥1,837 million / Operating profit ¥453 million |
| Full-year earnings forecast | Fiscal year ending June 2027 Net Sales ¥7,535 million / Operating profit ¥1,569 million / Ordinary income ¥1,569 million / Profit attributable to owners of the parent ¥1,005 million / EBITDA ¥1,954 million |
| Self-assessment against the plan | All revenue and profit targets at each level were achieved |
| Segment results | Animal hospital network business Net Sales ¥5,763 million / Ordinary income ¥1,046 million / Operating margin 18.1% / Medical and hygiene equipment business Net Sales ¥268 million / Ordinary income ¥64 million / Operating margin 23.8% / Biomaterials Business Net Sales Not disclosed / Ordinary income Not disclosed / Operating margin 0.0% / Medical data solutions business Net Sales ¥125 million / Ordinary income ¥22 million / Operating margin 17.8% / Contract research and development business Net Sales Not disclosed / Ordinary income Not disclosed / Operating margin 0.0% |
| Breakdown of Factors Affecting the Change | Operating profit Revenue increase ¥692 million / Personnel Expenses ¥-242 million / Procurement ¥-98 million / Goodwill amortization ¥-19 million / Other ¥-115 million |
| Key KPIs | Indicator name EBITDA / Value ¥1,511 million / Year on year against the same period last year +20.0%, Indicator name EBITDA margin / Value 24.6 % / Year on year against the same period last year +1.5 percentage points, Indicator name Number of animal hospitals / Value 39 Hospitals / Year on year against the same period last year +1 hospital, Indicator name Number of medical cases / Value 12.5 ten thousand items / Year on year against the same period last year Increased, Indicator name Average medical service price / Value ¥448 thousand / Year on year against the same period last year Increased |
| Unit price and quantity metrics | Number of medical cases 12.5 ten thousand items / Average medical service price ¥448 thousand |
| Number of stores and locations | End of period 39 Hospitals/sites / Number of store openings and closures during the period 21 sites acquired through business succession, a net increase of 5 self-established sites, and 4 closures |
| Assumptions Underlying the Business Outlook | New M&A Not included in the forecast due to uncertainty over the timing of opening / New Hospital Openings Not included in the forecast due to uncertainty over the timing of opening / Scope Assumes only revenue growth from existing businesses and confirmed M&A transactions |
| Annual Dividend | An initial dividend is scheduled to be paid from the fiscal year ending June 2027; the dividend per share is not disclosed |
| Payout ratio | Based on a 20% payout ratio |
| Capital expenditures | ¥189 million (acquisitions of property, plant and equipment) |
| New initiatives | Strategic M&A to build a One Health platform, Launch of sales of Photo Barrier405, Planned launch of the Craft model disinfecting and deodorizing machine, Proof-of-concept research on technology to inactivate avian influenza viruses, Succession of the chitin nanofiber business and opening of the Tottori Factory, Joint research with DynaCom on the use of veterinary medical data, Making メディトリックス a wholly owned subsidiary, Appointment of Dr. Ichikawa Yasuaki (市川康明) as co-director of the Institute of Advanced Veterinary Medicine |
Items this document does not state (11)
Gross Profit MarginSelling, general and administrative expensesProgress against full-year forecastNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to organic growth at existing hospitals, the full-year contribution from バハティー following its M&A in the previous fiscal year, and contributions from 飛鳥メディカル㈱, See㈱ and カルテック㈱ following their M&A transactions during the current fiscal year. Although one-time M&A-related costs and higher personnel expenses were incurred, operating profit benefited from greater operating efficiency through group management, cost synergies, revisions to medical service pricing and the expansion of medical equipment.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.